Edition:
United States

People: ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

9.47USD
16 Feb 2018
Change (% chg)

$0.07 (+0.74%)
Prev Close
$9.40
Open
$9.42
Day's High
$9.58
Day's Low
$9.35
Volume
21,816
Avg. Vol
40,509
52-wk High
$10.80
52-wk Low
$5.45

Charo, Israel 

Dr. Israel F. Charo, M.D., Ph.D., has been appointed as Senior Vice President - Research of ChemoCentryx, Inc. Prior to joining us, Dr. Charo was a Scientist-in-Residence at Bay City Capital since 2009. Dr. Charo has also served as a Senior Investigator at the Gladstone Institute of Cardiovascular Disease, and Professor of Medicine at University of California, San Francisco (UCSF) since 1991. He studies the role of chemokines in leukocyte trafficking and inflammation. His group cloned the chemokine receptor known as CCR2, and showed that it is a major driver for the recruitment of monocyte/macrophages to developing atherosclerotic lesions. Prior to that, Dr. Charo was one of the founding scientists of COR Therapeutics, Inc. (subsequently acquired by Millennium Pharmaceuticals, Inc.) from 1988 until 1991, where he was part of the team that developed the platelet inhibitor Integrilin. Dr. Charo received his M.D. and Ph.D. from State University of New York Downstate, and is trained in internal medicine at The New York Hospital, Weill Medical Center and Rheumatology at UCSF. Dr. Charo received his B.S. and M.S. in Engineering and Materials Science from SUNY Stony Brook, New York and University of California, Berkeley, respectively.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Thomas Schall

2,635,940

Susan Kanaya

1,456,890

William Fairey

--

Israel Charo

--

Markus Cappel

1,774,220

Roger Lucas

--
As Of  30 Dec 2014